Christophe Borg

19.5k total citations · 3 hit papers
227 papers, 6.3k citations indexed

About

Christophe Borg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Christophe Borg has authored 227 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 45 papers in Surgery. Recurrent topics in Christophe Borg's work include Colorectal Cancer Treatments and Studies (92 papers), Cancer Treatment and Pharmacology (36 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Christophe Borg is often cited by papers focused on Colorectal Cancer Treatments and Studies (92 papers), Cancer Treatment and Pharmacology (36 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Christophe Borg collaborates with scholars based in France, United States and Spain. Christophe Borg's co-authors include Olivier Bouché, Jaafar Bennouna, François Ghiringhelli, Thierry André, Eric Van Cutsem, Camille Grandclément, Xavier Pivot, Olivier Adotévi, C. Schlichting and Belguendouz Bendahmane and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

Christophe Borg

211 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

2012 829 citations Jaafar Bennouna, Eric Van Cutsem et al. profile →
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

2008 726 citations Christophe Borg et al. profile →
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

2024 57 citations Thierry Conroy, Florence Castan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christophe Borg France	39	4.3k	1.7k	1.2k	1.1k	1.1k	227	6.3k
Alessandro Rizzo Italy	57	3.3k 0.8×	2.6k 1.5×	1.6k 1.4×	687 0.6×	2.0k 1.9×	220	6.5k
Hans Prenen Belgium	41	4.0k 0.9×	2.6k 1.5×	2.6k 2.3×	1.3k 1.2×	1.3k 1.2×	207	8.6k
Yuxian Bai China	37	3.2k 0.7×	2.3k 1.3×	1.5k 1.3×	511 0.5×	1.2k 1.1×	187	6.0k
Francesco Graziano Italy	43	3.3k 0.8×	1.8k 1.0×	1.8k 1.6×	489 0.4×	1.3k 1.2×	163	5.8k
Gary Middleton United Kingdom	41	5.4k 1.2×	4.2k 2.4×	1.3k 1.1×	1.4k 1.3×	2.0k 1.8×	176	8.9k
Michael J. Pishvaian United States	40	3.8k 0.9×	1.1k 0.6×	1.9k 1.7×	831 0.8×	747 0.7×	216	5.8k
Moritz Koch Germany	46	4.6k 1.1×	1.5k 0.9×	2.2k 1.9×	1.2k 1.1×	1.8k 1.7×	98	7.8k
Dimitrios Pectasides Greece	43	2.9k 0.7×	1.2k 0.7×	1.7k 1.5×	690 0.6×	1.3k 1.2×	227	6.1k
Tae Won Kim South Korea	44	5.1k 1.2×	2.5k 1.5×	1.3k 1.1×	428 0.4×	1.7k 1.5×	296	7.5k
Emmanuel Quinaux Belgium	18	4.2k 1.0×	1.3k 0.8×	656 0.6×	560 0.5×	625 0.6×	37	4.9k

Countries citing papers authored by Christophe Borg

Since Specialization

Citations

This map shows the geographic impact of Christophe Borg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Borg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Borg more than expected).

Fields of papers citing papers by Christophe Borg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Borg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Borg. The network helps show where Christophe Borg may publish in the future.

Co-authorship network of co-authors of Christophe Borg

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Borg. A scholar is included among the top collaborators of Christophe Borg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Borg. Christophe Borg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spehner, Laurie, Adeline Bouard, Marie Kroemer, et al.. (2025). Clinical and biological determinants of multimodal metronomic chemotherapy efficacy in chemo‐refractory gastrointestinal cancers. International Journal of Cancer. 158(1). 182–192.

Truntzer, Caroline, David Rageot, Françoise Beltjens, et al.. (2024). Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. Biomedicines. 12(12). 2754–2754. 1 indexed citations

Bachet, Jean‐Baptiste, Déwi Vernerey, Christophe Boisson, et al.. (2024). 532P G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study. Annals of Oncology. 35. S447–S447. 1 indexed citations

Caulet, Morgane, Olivier Bouché, Christophe Borg, et al.. (2024). Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer. Digestive and Liver Disease. 57(1). 141–148. 1 indexed citations

Monnien, Franck, Sophie Félix, Zohair Selmani, et al.. (2024). Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer. Diagnostic Pathology. 19(1). 88–88. 3 indexed citations

Borg, Christophe, V. Vendrely, Thierry André, et al.. (2023). 651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study. Annals of Oncology. 34. S456–S457. 1 indexed citations

Ciardiello, Fortunato, Yung‐Jue Bang, Andrés Cervantes, et al.. (2023). Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results. Cancer Medicine. 12(12). 13145–13154. 6 indexed citations

Mollévi, Caroline, Sophie Gourgou, Christophe Borg, et al.. (2023). Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis. European Journal of Cancer. 186. 151–165. 22 indexed citations

Rasola, Cosimo, Pierre Laurent‐Puig, Thierry André, et al.. (2023). Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer. European Journal of Cancer. 194. 113321–113321. 5 indexed citations

10.

Cutsem, Eric Van, Iwona Danielewicz, Mark Saunders, et al.. (2022). First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. British Journal of Cancer. 126(11). 1548–1554. 9 indexed citations

11.

Jary, Marine, Angélique Vienot, Romain Loyon, et al.. (2020). Molecular description of ANGPT2 associated colorectal carcinoma. International Journal of Cancer. 147(7). 2007–2018. 22 indexed citations

12.

Royer, Bernard, Antonin Schmitt, Thierry Nguyen, et al.. (2020). Exposure‐response analysis of Raltitrexed assessing liver toxicity. British Journal of Clinical Pharmacology. 87(3). 1327–1337. 4 indexed citations

13.

Spehner, Laurie, Stéfano Kim, Angélique Vienot, et al.. (2020). Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials. International Journal of Molecular Sciences. 21(18). 6838–6838. 15 indexed citations

14.

Joseph, Elodie Lauret Marie, Caroline Laheurte, Marine Jary, et al.. (2019). Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(2). 268–279. 33 indexed citations

15.

Laheurte, Caroline, Fabien Calcagno, Laura Boullerot, et al.. (2019). Metronomic cyclophosphamide induces regulatory T cells depletion and PSA‐specific T cells reactivation in patients with biochemical recurrent prostate cancer. International Journal of Cancer. 147(4). 1199–1205. 14 indexed citations

16.

Jary, Marine, Déwi Vernerey, Thierry Lecomte, et al.. (2015). Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 24(3). 603–612. 16 indexed citations

17.

Dosset, Magalie, Yann Godet, Charline Vauchy, et al.. (2012). Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. Clinical Cancer Research. 18(22). 6284–6295. 47 indexed citations

18.

Bedel, Romain, Antoine Thiery-Vuillemin, Camille Grandclément, et al.. (2011). Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells. Cancer Research. 71(5). 1615–1626. 94 indexed citations

19.

Borg, Christophe, Julien Taı̈eb, Magali Terme, et al.. (2003). Immunothérapie fondée sur les cellules natural killer : implication des cellules dendritiques. Bulletin du Cancer. 90(8). 699–705. 1 indexed citations

20.

Borg, Christophe & V. Trillet-Lenoir. (2001). Introduction to the principles of chemotherapy dose intensity. Bulletin du Cancer. 88(9). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact